Cephamycin related to 2nd generation cephalosporins, the use of cefoxitin has long been limited to antibiotic prophylaxis. Because of its spectrum (sensitive staphylococci, enterobacteria including ESBL, streptococci, anaerobes), its stability and its low cost, it could be useful in curative bone and joint infections, especially in case of infection polymicrobial disease in patients for whom antibiotic alternative per os is limited.
Study Type
OBSERVATIONAL
Enrollment
35
the patients had cefoxitin in combination in continuous parenteral administration to treat their bone / joint infection
Hospices Civils de Lyon
Lyon, France
Rate of Treatment Failure
Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin
Time frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
Rate of use of this strategy
Descriptions of patients managed with this strategy
Time frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.